Merck broke ground on a $1 billion, 470,000-square-foot state-of-the-art biologics center of excellence in Wilmington, Del., the Rahway-based company announced April 29. The Merck Wilmington Biotech ...

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter. Merck is constructing a $1 billion drug ...

Merck (NYSE:MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical company to boost domestic investment as industry-targeted tariffs loom. This 470 ...

Merck (MRK) Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA A cornerstone of Merck’s continued commitment to investing in American ...

A Delaware jury has ordered Gilead Sciences to pay $2.54 billion in damages to Merck for infringing a patent related to hepatitis C treatment. It is the largest-ever patent damages award A jury in the ...

Merck & Co. continues to be liable for its talc-related litigation, despite attempts to shift responsibility to Bayer. A Delaware judge dismissed Merck’s suit against Bayer in which it tried to hand ...

Merck's $70 billion US investment plan includes a $3 billion facility in Virginia, creating 500 jobs and enhancing pharmaceutical manufacturing capabilities. Additional investments include a $1 ...

(Reuters) -U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Donald Trump's tariffs. The new ...

The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC:BAYRY) (OTC:BAYZF), stating that the company is not accountable for lawsuits associated with talc-based foot powder products ...

Justices on the Delaware Supreme Court on Wednesday pushed a Merck attorney to justify his interpretation of liability in a contract, seeking an explanation for why the company has changed its stance ...

As we previously reported, Sanofi-Aventis sued Merck Sharp & Dohme in the District of Delaware for patent infringement based on Merck’s proposed follow-on biologics of Sanofi-Aventis’s Lantus® and ...